一種新研制的對抗耐甲氧西林金黃色葡萄球菌（MRSA）的新武器，具有持久滅菌包膜，能夠99.8%地限制MRSA的生長。

Biacticap正在被用于作為無碳紙張的包膜，獨立的檢測結果發現其能夠有效地抑制MRSA的生長。用于醫生筆記本和患者病歷的紙張是各種細菌包括MRSA的良好的宿主和攜帶者，能夠在醫生與患者之間、患者與醫院雇員之間、以及醫院不同科室之間引起交叉感染。

Biacticap是由Carrs產品公司研制開發的，這是一家生產包膜紙張的制造商。這種包膜能夠有效對抗細菌，包括李斯特菌、大腸桿菌和沙門氏菌。Carrs公司計劃擴大治療范圍，將其擴展至柔軟的物質例如塑料、薄膜、非紡織品物質、以及紡織品，這樣Biacticap就可以保護絕大多數醫院內的柔軟的表面。

Carrs公司市場與銷售部主任Tony Davis說：“由于突變，細菌能夠迅速對抗生素產生抵抗，因此是一種潛在的健康威脅。不同的是，Biacticap是無機產品，能夠對細菌突變提供持續的保護作用，而且細菌突變不會對它的抗微生物作用產生免疫。”
 
New Weapon Against Superbugs
 
A newly developed weapon against superbug methicillin-resistant Staphylococcus aureus (MRSA) is a permanent biocidal coating that is 99.8% effective in limiting the growth of MRSA.

Biacticap is being used as a coating for carbonless paper, where independent testing has found it to be effective in limiting the growth of MRSA. Paper, used for doctors’ notes and patient records, is an excellent host and carrier for all types of bacteria including MRSA, serving as a mechanism for cross-contamination between doctors and patients, patients and hospital employees, and between different hospital departments.

Biacticap was developed by Carrs Products (Birmingham, UK), a manufacturer of coated papers. The coating is also effective against other bacteria, including Listeria, Escherichia coli, and Salmonella. Carrs Products plans to extend the treatment to other flexible substrates such as plastics, film, nonwoven materials, and textiles, so that Biacticap would be able to protect most flexible surfaces in the hospital.

“Bacteria can quickly become resistant to antibiotics as a result of mutation, and therefore represent an ongoing healthcare threat,” said Tony Davis, sales and marketing director of Carrs Products. “In contrast, because Biacticap is inorganic, it provides continuous protection against bacteria mutations, which cannot become immune to its antimicrobial action.”